Skip to main content

Edesa Biotech, Inc.

EDSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001540159

No open-market purchases or sales by Edesa Biotech, Inc. insiders were filed in the last 90 days; 33 institutions reported holding it in 13F filings for Q2 2026, worth $30.0M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Edesa Biotech, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of EDSA: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders2019−1
SharesConverted for a 1-for-7 split293.2K110.8K−182.3K (−62.2%)
Value$1.26M$507.1K−$754.5K (−59.8%)

New holders (4)

Institutions that held Edesa Biotech, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to EDSA in Q4 2023
InstitutionSharesValue% of portfolio
Dimensional Fund Advisors LP11,333$52.0K0.00%
Global Wealth Strategies & Associates7$320.00%
Citigroup Inc2$90.00%
Credit Agricole S A1$50.00%

Sold out (5)

Institutions that held Edesa Biotech, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of EDSA in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Velan Capital Investment Management LP1,281,615$810.0K
State Street Corp43,975$27.5K
Northern Trust Corp22,540$14.2K
Advisor Group Holdings, Inc.8$5
CIBC World Markets Inc.54,626–